Clinical Trials
13 trialsNCT05813327 2026-04-20
Neoadjuvant ADI-PEG 20 + Ifosfamide + Radiotherapy in Soft Tissue Sarcoma
Washington University School of Medicine
Phase 1 Active not recruiting
NCT05001828 2026-01-21
Study of ADI-PEG 20, Venetoclax and Azacitidine in Acute Myeloid Leukemia
Polaris Group
Phase 1 Active not recruiting
NCT03922880 2025-05-15
Study of Immunotherapy Plus ADI-PEG 20 for the Treatment of Advanced Uveal Melanoma
Memorial Sloan Kettering Cancer Center
Phase 1 Completed
NCT03254732 2022-04-27
Study ADI-PEG 20 Plus Pembrolizumab in Advanced Solid Cancers
Polaris Group
Phase 1 Terminated
NCT02101580 2020-10-01
Ph 1B Trial With ADI-PEG 20 Plus Nab-Paclitaxel and Gemcitabine in Subjects With Pancreatic Cancer
Polaris Group
Phase 1 Completed
NCT02029690 2020-09-25
TRAP
Polaris Group
Phase 1 Terminated
NCT02875093 2020-03-05
Ph 1 Study of ADI-PEG 20 Plus Low Dose Cytarabine in Older Patients With AML
Polaris Group
Phase 1 Terminated
NCT03498222 2020-02-25
iTRAP
Queen Mary University of London
Phase 1 Withdrawn
NCT01497925 2018-09-13
Ph 1 Trial of ADI-PEG 20 Plus Docetaxel in Solid Tumors With Emphasis on Prostate Cancer and Non-Small Cell Lung Cancer
Polaris Group
Phase 1 Completed
NCT01948843 2016-04-14
Ph 1 ADI-PEG 20 Plus Doxorubicin; Patients With HER2 Negative Metastatic Breast Cancer
Polaris Group
Phase 1 Completed
NCT02101593 2016-03-04
Ph 1 Trial of ADI PEG 20 Plus Sorafenib to Treat Patients With Liver Cancer
Polaris Group
Phase 1 Completed
NCT01665183 2016-02-25
Ph 1 Trial of ADI-PEG 20 Plus Cisplatin in Patients With Metastatic Melanoma
Polaris Group
Phase 1 Completed
NCT00029900 2015-03-25
ADI-PEG in Patients With Metastatic Melanoma
FDA Office of Orphan Products Development
Phase 1 Completed